NCT05636319进行中（未招募）2 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 14,168
- 试验地点
- 29
- 主要终点
- In Phase 3, efficacy after the second dose
研究概览
简要总结
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntarily sign the ICF approved by the Ethics Committee before any study procedure and agree to participate in the study.
- •Healthy male or female able to provide legal identity certificate and aged 18 years and older when signing the ICF.
- •Subjects who have previously been fully vaccinated either by 2 or 3 doses of SARS-CoV-2 inactivated vaccine. The last dose of immunization should be >6 months before administration of the investigational products.
- •Be able to communicate well with the investigator, and to understand and comply with the requirements of this clinical trial.
- •Males and females with childbearing potential voluntarily take effective contraceptive methods from signing ICF to 3 months after completing the vaccination, including sexual abstinence or effective contraceptive measures (e.g., intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, intrauterine device [IUD], condoms [male], diaphragm, and cervical cap).
排除标准
- •Positive SARS-CoV-2 rapid test at screening.
- •Prior medical history of severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS).
- •Fever (axillary temperature or equivalent ≥ 37.3℃*) on the day of vaccination with this investigational vaccine or within recent 72 hours.
- •Abnormal vital signs (pulse < 60 bpm or > 100 bpm, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg when keeping awake) with clinical relevance.
- •Do not remain overall healthy (i.e., has medically deteriorated significantly since receiving the two-dose vaccination, is anticipated to have fatal outcome of uncontrolled diseases within 12 months, and is not able to provide blood as specified by the trial with anticipated, deleterious medical consequences) in the clinical judgment of the investigator based on medical history and physical examination.
- •Pregnant or lactating women, or those who plan to donate sperm or egg during the trial.
- •Prior history of allergic reaction or anaphylaxis to any vaccine or its excipients, e.g., hypersensitivity, urticaria, serious eczema, dyspnea, laryngeal edema, and angioedema etc.
- •Prior use of any other vaccine within 28 days before using the investigational products or planning to use any vaccine other than the investigational products during the study period.
- •Participation in the studies of any other interventional device or drug within 30 days before the screening, or current treatment with other investigational drug(s) or within 5 half-lives after taking the last dose of the study drug.
- •Hereditary hemorrhagic tendency or coagulation dysfunction (e.g., cytokine defects, coagulation disorders or platelet disorder), or a history of serious bleeding, or a history of massive bleeding after intramuscular injection or intravenous puncture or ecchymosis.
- •Known medical history or diagnosis confirming that subjects have diseases affecting immune system function, including cancer (except skin basal cell carcinoma), congenital or acquired immunodeficiency (e.g., infection with human immunodeficiency virus [HIV]), and uncontrolled autoimmune disease.
- •Serious or uncontrolled respiratory system disorders, cardiovascular disorders, nervous system disorders, blood and lymphatic system disorders, liver and kidney disorders, metabolism and skeletal disorders,etc. influencing study results evaluation at the investigator's discretion.
- •Asplenia or functional asplenia.
- •Long-term use (continuous use ≥14 days) of immunosuppressants or other immunomodulators (e.g., glucocorticoids: prednisone or similar drugs) within 6 months prior to administration of this investigational vaccine, except for topical medications (e.g., ointments, eye drops, inhalants or nasal sprays). And the topical medications should not exceed the recommended dose in the labels for use or induce any signs of systemic exposure.
- •Having received immunoglobulins and/or blood products within 3 months prior to administration of this investigational vaccine.
- •Suspected or known alcohol dependency or drug abuse, which may affect safety evaluation or subject's compliance at the investigator's discretion.
- •Planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits.
- •Receiving antituberculosis treatment.
- •Staff of study site, sponsor and contract research organization (CRO) taking part in the study.
- •Other conditions that the investigators consider unsuitable for this study.
结局指标
主要结局
In Phase 3, efficacy after the second dose
时间窗: 14 days after second dose
Confirmed COVID-19 cases occurring from 14 days after the second dose
In Phase 1/2, Incidence of unsolicited adverse events
时间窗: 0 to 28 days after each dose
Unsolicited adverse events 0 to 28 days after each dose
In Phase 1/2, Incidence of solicited adverse events
时间窗: 0 to 14 days after each dose
Solicited adverse events 0 to 14 days after each dose
次要结局
- In Phase 1/2, titer of Anti-SARS-CoV-2 live virus neutralizing antibody(28 days after each dose and the corresponding ratio against Day 0 before the vaccination.)
- In Phase 3, titer of Anti-SARS-CoV-2 live virus neutralizing antibody(28 days after each dose, 90 days and 180 days after the second dose and the corresponding ratio against Day 0 before the vaccination.)
- In Phase 3, Observation of long-term Safety(12 months after each dose)
- In Phase 1/2, Observation of Long-term Safety(12 months after each dose)
研究者
研究点 (29)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisPulmonary Fibrosis Secondary to Systemic SclerosisPulmonary Fibrosis, Interstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)Interstitial Lung Disease in Patients With Rheumatoid ArthritisInterstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified ElsewhereInterstitial Lung Disease With Systemic SclerosisPulmonary FibrosisHypersensitivity PneumonitisInterstitial Lung DiseaseNCT06329401Avalyn Pharma Inc.375
已完成
不适用
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver HealthNon-Alcoholic Fatty Liver DiseaseNCT05808049Vedic Lifesciences Pvt. Ltd.60
已完成
2 期
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract InfectionsAcute PyelonephritisComplicated Urinary Tract InfectionNCT03445195Entasis Therapeutics80
进行中（未招募）
3 期
Clinical Study of Divozilimab in Patients With Systemic SclerodermaSystemic SclerodermaNCT05726630Biocad152
已完成
2 期
Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in FilipinosPediculosis CapitisNCT03286101United Laboratories120